Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients

NCT04826393 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04826393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04826393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
March 9, 2022
Completion date
January 1, 2024
Enrollment
14 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, recurrent glioblastoma